174 related articles for article (PubMed ID: 22272748)
1. Fragment-based and structure-guided discovery and optimization of Rho kinase inhibitors.
Li R; Martin MP; Liu Y; Wang B; Patel RA; Zhu JY; Sun N; Pireddu R; Lawrence NJ; Li J; Haura EB; Sung SS; Guida WC; Schonbrunn E; Sebti SM
J Med Chem; 2012 Mar; 55(5):2474-8. PubMed ID: 22272748
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel ROCK inhibitors with anti-migratory and anti-invasive activities.
Patel RA; Liu Y; Wang B; Li R; Sebti SM
Oncogene; 2014 Jan; 33(5):550-5. PubMed ID: 23396364
[TBL] [Abstract][Full Text] [Related]
3. RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer.
Patel RA; Forinash KD; Pireddu R; Sun Y; Sun N; Martin MP; Schönbrunn E; Lawrence NJ; Sebti SM
Cancer Res; 2012 Oct; 72(19):5025-34. PubMed ID: 22846914
[TBL] [Abstract][Full Text] [Related]
4. Distinct roles for ROCK1 and ROCK2 in the regulation of cell detachment.
Shi J; Wu X; Surma M; Vemula S; Zhang L; Yang Y; Kapur R; Wei L
Cell Death Dis; 2013 Feb; 4(2):e483. PubMed ID: 23392171
[TBL] [Abstract][Full Text] [Related]
5. Identification of 5H-chromeno[3,4-c]pyridine and 6H-isochromeno[3,4-c]pyridine derivatives as potent and selective dual ROCK inhibitors.
Hu Z; Wang C; Sitkoff D; Cheadle NL; Xu S; Muckelbauer JK; Adam LP; Wexler RR; Quan ML
Bioorg Med Chem Lett; 2020 Nov; 30(21):127474. PubMed ID: 32805407
[TBL] [Abstract][Full Text] [Related]
6. Targeting the metastasis suppressor, NDRG1, using novel iron chelators: regulation of stress fiber-mediated tumor cell migration via modulation of the ROCK1/pMLC2 signaling pathway.
Sun J; Zhang D; Zheng Y; Zhao Q; Zheng M; Kovacevic Z; Richardson DR
Mol Pharmacol; 2013 Feb; 83(2):454-69. PubMed ID: 23188716
[TBL] [Abstract][Full Text] [Related]
7. Activation of Rho kinase isoforms in lung endothelial cells during inflammation.
Mong PY; Wang Q
J Immunol; 2009 Feb; 182(4):2385-94. PubMed ID: 19201893
[TBL] [Abstract][Full Text] [Related]
8. Rho kinase signaling pathways during stretch in primary alveolar epithelia.
DiPaolo BC; Margulies SS
Am J Physiol Lung Cell Mol Physiol; 2012 May; 302(10):L992-1002. PubMed ID: 22287611
[TBL] [Abstract][Full Text] [Related]
9. Linking phenotype to kinase: identification of a novel benzoxaborole hinge-binding motif for kinase inhibition and development of high-potency rho kinase inhibitors.
Akama T; Dong C; Virtucio C; Sullivan D; Zhou Y; Zhang YK; Rock F; Freund Y; Liu L; Bu W; Wu A; Fan XQ; Jarnagin K
J Pharmacol Exp Ther; 2013 Dec; 347(3):615-25. PubMed ID: 24049062
[TBL] [Abstract][Full Text] [Related]
10. PKM2 phosphorylates MLC2 and regulates cytokinesis of tumour cells.
Jiang Y; Wang Y; Wang T; Hawke DH; Zheng Y; Li X; Zhou Q; Majumder S; Bi E; Liu DX; Huang S; Lu Z
Nat Commun; 2014 Nov; 5():5566. PubMed ID: 25412762
[TBL] [Abstract][Full Text] [Related]
11. Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases.
Sehon CA; Wang GZ; Viet AQ; Goodman KB; Dowdell SE; Elkins PA; Semus SF; Evans C; Jolivette LJ; Kirkpatrick RB; Dul E; Khandekar SS; Yi T; Wright LL; Smith GK; Behm DJ; Bentley R; Doe CP; Hu E; Lee D
J Med Chem; 2008 Nov; 51(21):6631-4. PubMed ID: 18842034
[TBL] [Abstract][Full Text] [Related]
12. Rho-kinase/myosin light chain kinase pathway plays a key role in the impairment of bile canaliculi dynamics induced by cholestatic drugs.
Sharanek A; Burban A; Burbank M; Le Guevel R; Li R; Guillouzo A; Guguen-Guillouzo C
Sci Rep; 2016 May; 6():24709. PubMed ID: 27169750
[TBL] [Abstract][Full Text] [Related]
13. Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design.
Hobson AD; Judge RA; Aguirre AL; Brown BS; Cui Y; Ding P; Dominguez E; DiGiammarino E; Egan DA; Freiberg GM; Gopalakrishnan SM; Harris CM; Honore MP; Kage KL; Kapecki NJ; Ling C; Ma J; Mack H; Mamo M; Maurus S; McRae B; Moore NS; Mueller BK; Mueller R; Namovic MT; Patel K; Pratt SD; Putman CB; Queeney KL; Sarris KK; Schaffter LM; Stoll V; Vasudevan A; Wang L; Wang L; Wirthl W; Yach K
J Med Chem; 2018 Dec; 61(24):11074-11100. PubMed ID: 30384606
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular effects of a novel selective Rho kinase inhibitor, 2-(1H-indazole-5-yl)amino-4-methoxy-6-piperazino triazine (DW1865).
Oh KS; Oh BK; Park CH; Seo HW; Kang NS; Lee JH; Lee JS; Ho Lee B
Eur J Pharmacol; 2013 Feb; 702(1-3):218-26. PubMed ID: 23376156
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a phenylpyrazole amide ROCK inhibitor as a tool molecule for in vivo studies.
Hu Z; Wang C; Glunz PW; Li J; Cheadle NL; Chen AY; Chen XQ; Myers JE; Guarino VR; Rose A; Sack JS; Sitkoff D; Taylor DS; Xu S; Yan C; Zhang H; Zhang L; Hennan J; Adam LP; Wexler RR; Quan ML
Bioorg Med Chem Lett; 2020 Nov; 30(21):127495. PubMed ID: 32798651
[TBL] [Abstract][Full Text] [Related]
16. Maturation and the role of PKC-mediated contractility in ovine cerebral arteries.
Goyal R; Mittal A; Chu N; Shi L; Zhang L; Longo LD
Am J Physiol Heart Circ Physiol; 2009 Dec; 297(6):H2242-52. PubMed ID: 19749163
[TBL] [Abstract][Full Text] [Related]
17. Protein kinase A inhibitor, H89, enhances survival and clonogenicity of dissociated human embryonic stem cells through Rho-associated coiled-coil containing protein kinase (ROCK) inhibition.
Zhang L; Xu Y; Xu J; Wei Y; Xu X
Hum Reprod; 2016 Apr; 31(4):832-43. PubMed ID: 26848187
[TBL] [Abstract][Full Text] [Related]
18. Biochemical, cellular, and anti-inflammatory properties of a potent, selective, orally bioavailable benzamide inhibitor of Rho kinase activity.
Rajagopalan LE; Davies MS; Kahn LE; Kornmeier CM; Shimada H; Steiner TA; Zweifel BS; Wendling JM; Payne MA; Loeffler RF; Case BL; Norton MB; Parikh MD; Nemirovskiy OV; Mourey RJ; Masferrer JL; Misko TP; Kolodziej SA
J Pharmacol Exp Ther; 2010 Jun; 333(3):707-16. PubMed ID: 20228155
[TBL] [Abstract][Full Text] [Related]
19. ROCK isoform regulation of myosin phosphatase and contractility in vascular smooth muscle cells.
Wang Y; Zheng XR; Riddick N; Bryden M; Baur W; Zhang X; Surks HK
Circ Res; 2009 Feb; 104(4):531-40. PubMed ID: 19131646
[TBL] [Abstract][Full Text] [Related]
20. Deleted in liver cancer 1 (DLC1) negatively regulates Rho/ROCK/MLC pathway in hepatocellular carcinoma.
Wong CC; Wong CM; Ko FC; Chan LK; Ching YP; Yam JW; Ng IO
PLoS One; 2008 Jul; 3(7):e2779. PubMed ID: 18648664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
